Information Provided By:
Fly News Breaks for February 6, 2020
Feb 6, 2020 | 06:29 EDT
JMP Securities analyst David Turkaly raised his price target on Zimmer Biomet to $175 and kept his Outperform rating after its Q4 beat on earnings and revenue thanks to the strength of its Knee and Hip businesses. The analyst adds that the company's outlook for FY20 sales growth of 2.5%-3-5% is a "step up" from the market average growth rate and was also higher than the consensus 2.5%. Turkaly adds that Zimmer's plans for multi-year restructuring should drive "meaningful upside" in the years ahead.
News For ZBH From the Last 2 Days
There are no results for your query ZBH